Clinical Trial Update: Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pediatric autologous bone marrow mononuclear cells for severe traumatic brain injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Traumatic Brain Injury | Phase 2 | Status: COMPLETED